Ameritas Investment Partners, Inc. Morphic Holding, Inc. Transaction History

Ameritas Investment Partners, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $6,942 - $10,788	348 Added 10.07%	3,804 $109,000
Q3 2023 Nov 13, 2023	BUY	$21.33 - $59.42 $20,114 - $56,033	943 Added 37.52%	3,456 $79,000
Q2 2023 Aug 11, 2023	BUY	$34.33 - $62.11 $19,121 - $34,595	557 Added 28.48%	2,513 $144,000
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $7,335 - $11,012	330 Added 20.3%	1,956 $55,000
Q2 2021 Aug 06, 2021	BUY	$45.13 - $64.99 $18,774 - $27,035	416 Added 34.38%	1,626 $93,000
Q2 2020 Aug 05, 2020	BUY	$12.65 - $29.57 $3,542 - $8,279	280 Added 30.11%	1,210 $33,000
Q1 2020 May 13, 2020	BUY	$10.84 - $20.85 $5,745 - $11,050	530 Added 132.5%	930 $14,000
Q3 2019 Nov 14, 2019	BUY	$17.46 - $29.05 $6,984 - $11,620	400 New	400 $7,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.